Key Drivers
- High profitability
- Large net debt
- Q4 margin pressure
AIAI Summary
Bristol‑Myers Squibb has shifted from a cash‑cow to a pipeline‑driven growth profile—offering asymmetric upside if near‑term pivotal readouts succeed and management delivers the $10B+ deleveraging and $2B cost‑savings, but heavy leverage, high R&D spend and margin sensitivity make those deliverables the single biggest determinants of valuation and dividend safety, so monitor quarterly FCF conversion, debt‑paydown cadence, and upcoming registrational outcomes.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Large net debt
- •Q4 margin pressure
BMY combines very strong profitability and cash generation with a moderate valuation and attractive yield, but its heavy leverage, Q4 margin weakness and high intangible/R&D base raise sustainability and impairment risks.
Price Behavior
Key Price Behavior Insights:
- •Below 21-day SMA
- •Near support floor
- •Distribution from peak
BMY is in a short-term downtrend: last month's SMA near $60.40 sits above the $57.48 close, ~5% lower month-over-month with resistance around $62.30 and support near $57–$58, implying distribution rather than a shallow pullback and a possible mean-reversion entry if fundamentals align.
Decline from early
Sentiment & News
Key News Insights:
- •Reblozyl growth
- •Mixed institutional flows
- •Value/dividend appeal
Bristol Myers is drawing renewed investor interest and mixed institutional moves as Reblozyl-driven revenue growth and a stronger late-stage pipeline bolster a value/dividend narrative amid recent short-term share strength.
These developments support potential medium-term upside and a valuation rerating, though near-term volatility from sector sentiment could persist
Similar Companies in Healthcare
Other companies in the same sector with AI ratings